Enanta Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference
Enanta Pharmaceuticals to Present at the 8thAnnual JMP Securities Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NAS: ENTA) , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a corporate overview followed by a Q&A session at 10:30 a.m. ET on July 9, 2013 during the 8th Annual JMP Securities Healthcare Conference in New York.
The presentation will be webcast live and a replay can be accessed by visiting the Investor homepage section of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes - protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase - as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a current focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections.
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
KEYWORDS: United States North America Massachusetts New York
The article Enanta Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.